Tech Company Financing Transactions

Aerpio Pharmaceuticals Funding Round

Aerpio Pharmaceuticals closed a $22 million funding round on 4/23/2014. Investors included OrbiMed, Athenian Venture Partners and Kearny Venture Partners.

Transaction Overview

Company Name
Aerpio Pharmaceuticals
Announced On
4/23/2014
Transaction Type
Venture Equity
Amount
$22,000,000
Round
Undisclosed
Investors

OrbiMed (Lead Investor) (Chau Khuong)

Athenian Venture Partners (Daniel Kosoy)

Kearny Venture Partners (Anupam Dalal)

Novartis Venture Fund (Campbell Murray)

Satter Investment Management (Muneer Satter )

Triathlon Medical Ventures

Venture Investors (Paul Weiss)

Proceeds Purpose
Proceeds will support expanded development of AKB-9778, a small molecule activator of Tie2, currently in a Phase 2 trial for the treatment of diabetic macular edema (DME), and the advancement of AKB-4924, a small-molecule HIF1 activator, into clinical development for inflammatory bowel disease (IBD).

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
9987 Carver Rd. 420
Cincinnati, OH 45242
USA
Phone
(513) 985-1920
Website
www.aerpio.com
Email Address
[email protected]
Overview
Aerpio Pharmaceuticals, a biopharmaceutical company,develops first-in-class treatments for ocular diseases.
Profile
Aerpio Pharmaceuticals LinkedIn Company Profile
Social Media
Aerpio Pharmaceuticals Company Twitter Account
Company News
Aerpio Pharmaceuticals News
Facebook
Aerpio Pharmaceuticals on Facebook
YouTube
Aerpio Pharmaceuticals on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Stephen Hoffman
  Stephen Hoffman LinkedIn Profile  Stephen Hoffman Twitter Account  Stephen Hoffman News  Stephen Hoffman on Facebook
Chief Financial Officer
Michael Rogers
  Michael Rogers LinkedIn Profile  Michael Rogers Twitter Account  Michael Rogers News  Michael Rogers on Facebook
Chief Medical Officer
Steve Pakola
  Steve Pakola LinkedIn Profile  Steve Pakola Twitter Account  Steve Pakola News  Steve Pakola on Facebook
Chief Scientific Officer
Kevin Peters
  Kevin Peters LinkedIn Profile  Kevin Peters Twitter Account  Kevin Peters News  Kevin Peters on Facebook
President
Joseph Gardner
  Joseph Gardner LinkedIn Profile  Joseph Gardner Twitter Account  Joseph Gardner News  Joseph Gardner on Facebook
Vice President
Brandi Soldo
  Brandi Soldo LinkedIn Profile  Brandi Soldo Twitter Account  Brandi Soldo News  Brandi Soldo on Facebook
VP - Bus. Development
Mitchell Brigell
  Mitchell Brigell LinkedIn Profile  Mitchell Brigell Twitter Account  Mitchell Brigell News  Mitchell Brigell on Facebook
VP - Finance
Gina Marek
  Gina Marek LinkedIn Profile  Gina Marek Twitter Account  Gina Marek News  Gina Marek on Facebook

 

 

Browse more venture capital transactions:

Prev: 4/23/2014: Yerdle venture capital transaction
Next: 4/23/2014: XAPPmedia venture capital transaction

 

Share this article

 

News on VC Transactions

We do our best to document funding rounds that are announced publicly. VC investment data records on this site are sourced from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.